Andrea Csonka, Annamária Kincses, Márta Nové, Zsófia Vadas, Carmen Sanmartín, Enrique Domínguez-Álvarez, Gabriella Spengler
Journal: Anticancer research 2019;39(7):3777-3783
PMID: 31262904
BACKGROUND/AIM
Selenium-containing compounds are becoming new alternatives in experimental chemotherapy in order to overcome multidrug resistance in cancer. The main goal of this study was to determine whether combined treatment with new Se-compounds would increase the effect of conventional doxorubicin chemotherapy in breast cancer cell lines.
MATERIALS AND METHODS
Se-compounds were evaluated regarding their cytotoxic and apoptosis-inducing effect on MCF-7 and ATP-binding cassette subfamily B member 1 (ABCB1)-overexpressing KCR breast cancer cell lines. Moreover, the interaction of Se-compounds with doxorubicin was assessed using the MTT assay.
RESULTS
Selenoanhydride exerted a selective activity towards the doxorubicin-resistant KCR cell line overexpressing ABCB1. Among the selenoesters, only ketone-containing selenoesters exerted significant cytotoxic activity against MCF-7 and KCR cell lines and the Se-compounds acted synergistically with doxorubicin on the KCR cell line.
CONCLUSION
The importance of the COSeCHCOCH and COSeCHCO(CH) moieties for the cytotoxic and adjuvant role of Se-compounds was highlighted.
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.